- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02439983
Brain Imaging Study
August 2, 2016 updated by: Pharmanex
A Randomized, Double-blind, Placebo-controlled Study Investigating the Effects of a Proprietary Nutritional Supplement on Brain Health
The study is designed to evaluate the effects of the proprietary nutritional supplement on cognition, mood, and brain imaging parameters following a relatively short period of treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
68
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University of Utah - Brain Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 60 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Both male and female subjects will be included.
- Age between 40-60 years inclusive.
- Healthy subjects who, in the opinion of the investigator, are free of any medical conditions that might affect study measures.
- Eats 1 or fewer servings of fatty fish per week.
- BMI < 35
Exclusion Criteria:
- Current or past neurological illness.
- Substance abuse or dependence within the prior 60 days.
- Current depression (HAMD greater than 20) or anxiety disorder (HAMA greater than 18).
- Current or past history of psychiatric disorder.
- History of head trauma with loss of consciousness.
- Contraindication to brain MRI examination.
- Supplementation with Omega 3, fish oil, or other over the counter supplements including the other bioactive ingredients in the proprietary nutritional supplement, antioxidants and multi-vitamin mineral supplements for the previous 3 months.
- Plasma Omega3 Index >5% at screening visit.
- Subject has a known allergy or intolerance to any of the ingredients contained in the proprietary nutritional supplement or placebo.
- Subject is currently pregnant, planning to become pregnant, or is breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
2 capsules taken by mouth with morning and evening meals.
|
|
Experimental: Proprietary Nutritional Supplement
|
2 capsules taken by mouth with morning and evening meals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in MRI Brain scan
Time Frame: Change from Baseline MRI Brain scan at Day 42
|
Determine differences in brain metabolism, brain connectivity, or brain structure.
Highlight regional brain changes between pre and post chronic supplementation with a proprietary nutritional formula.
|
Change from Baseline MRI Brain scan at Day 42
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in anxiety as measured by the Hamilton Anxiety Scale (HAM-A)
Time Frame: Change from Baseline anxiety at Day 42
|
Change from Baseline anxiety at Day 42
|
|
Change in depression as measured by the Hamilton Depression Rating Scale (HAM-D)
Time Frame: Change from Baseline depression at Day 42
|
Change from Baseline depression at Day 42
|
|
Change in mood as measured by the Profile of Mood States (POMS)
Time Frame: Change from Baseline mood at Day 42
|
Change from Baseline mood at Day 42
|
|
Change in memory as measured by Logical Memory I and II (subtests from the Wechsler Memory Scale- IV)
Time Frame: Change from Baseline memory at Day 42
|
Change from Baseline memory at Day 42
|
|
Change in fluency as measure by Letter and Category Fluency test
Time Frame: Change from Baseline fluency at Day 42
|
Change from Baseline fluency at Day 42
|
|
Change in Chemistry panel
Time Frame: Change from Baseline Chemistry panel at Day 42
|
Change from Baseline Chemistry panel at Day 42
|
|
Change in RBC fatty acid profile
Time Frame: Change from Baseline RBC fatty acid profile at Day 42
|
Change from Baseline RBC fatty acid profile at Day 42
|
|
Change in Gene expression
Time Frame: Change from Baseline Gene expression at Day 42
|
Change from Baseline Gene expression at Day 42
|
|
Measurement of polyphenol metabolites in saliva
Time Frame: Day 42
|
Day 42
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Deborah Yurgelun-Todd, Ph.D., University of Utah
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2015
Primary Completion (Actual)
June 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
April 30, 2015
First Submitted That Met QC Criteria
May 6, 2015
First Posted (Estimate)
May 12, 2015
Study Record Updates
Last Update Posted (Estimate)
August 3, 2016
Last Update Submitted That Met QC Criteria
August 2, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- 14-PHX-0002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Health
-
Wake Forest University Health SciencesTerminatedBrain Health | Brain Function | Brain DevelopmentUnited States
-
NeuroCatch Inc.Completed
-
NeuroCatch Inc.Completed
-
NeuroCatch Inc.Completed
-
Lumos Labs, Inc.Active, not recruitingCognition | Brain Health | Brain Function | Brain StructureUnited States
-
McMaster UniversityNot yet recruitingWomen's Health | Brain PlasticityCanada
-
University of Dublin, Trinity CollegeUnknownBrain Health Retired Elite Athletes
-
Vita Naturel, LLCUniversity of South Alabama; University of North Carolina at Asheville; Braini...Completed
-
University of Illinois at Urbana-ChampaignCompletedCognition | Brain Health | Scholastic AchievementUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of